Amicus Therapeutics FOLD announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top line currently comprises sales of the lead product, Galafold ...
PRINCETON, N.J., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback